Eli Lilly (LLY.US) Makes Another Move! Acquires Calytrix for Up to $1.5 Billion, Betting on Rare Blood Cancer Therapy
Zhitong Finance APP has learned that Eli Lilly (LLY.US) has agreed to acquire privately held Calytrix Bio Inc. in a deal valued at up to $1.5 billion. This is also Eli Lilly's latest move in its ongoing acquisitions and strategic positioning in the oncology and autoimmune disease sectors.
Latest

